Eliana Clark - 23 Feb 2022 Form 3 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Technical Officer
Signature: /s/ James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 23 Feb 2022
Net transactions value: $0
Form type: 3
Filing time: 07 Mar 2022, 18:15:06 UTC
Next filing: 07 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	NTLA	Common Stock						5,638	23 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NTLA	Stock Option (right to buy)							23 Feb 2022	Common Stock	62,750	$12.27	Direct	F2
holding	NTLA	Stock Option (right to buy)							23 Feb 2022	Common Stock	31,500	$57.71	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes a grant of 5,250 restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	This option was granted on February 3, 2020 with respect to 75,000 shares of Common Stock, with 25% vesting on January 6, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
F3	This option was granted on March 3, 2021 with respect to 31,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.